Two main approaches for gene therapy in DMD are delivery of engineered mini dystrophin (lacking non-essential domains) and up-regulation of utrophin that is one of the dystrophin isoforms (39, 40). The gene discussed is UTRN; the disease is Duchenne muscular dystrophy.